Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hi walterc,
do you know when to expect next milestone or news release?
Have there been an information about news in near future?
Thanks,
Yes, I agree.
But why is there not a 2/3 debt and 1/3 equity financing package?
Market is not impressed.
It may take 1-2 month till the closing of pp
Lucky you walter, I just started my working life 1988
Is Mark Smith CEO now?
Whats wrong with MIN?
Please note, that the following is just my opinion:
I guess it will take 1,5 to 2 years for theralase to gather enough momentum to reach big highs if all following human tests work out. For the super potent anti-cancer drug and the vaccines they have discovered.
But then sp can go to something between 0 - XXX $, depending on the kind of deal with big pharma and feature share dilition.
Everything is possible but it takes again a long time.
Please enlight me if I am wrong.
Theralase Therapeutic Laser Technology Enhances Cancer Destruction
Toronto, Ontario – November 27, 2017, Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotech company focused on the commercialization of medical lasers to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer has announced that its Theralase® therapeutic laser technology platform has been proven preclinically to render cancer cells more susceptible to cancer destruction by Photo Dynamic Therapy (“PDT”), by reversing the Warburg Effect.
One of the hallmarks of cancer cells is a change in cellular metabolism from mitochondrial respiration (the production of Adenosine TriPhosphate (“ATP”)) that relies on oxygen consumption to glycolysis, an oxygen independent process.
Cancer cells systematically modify their metabolism to promote their: growth, survival, proliferation and long-term maintenance, without the need for molecular oxygen, thus making them difficult to destroy by traditional means.
This common feature, amongst cancer cells, of a modified metabolism, is demonstrated by an increase in glucose (blood sugar) uptake and an increase in lactate production. This phenomenon was originally described by Dr. Otto Warburg at the turn of the 19th century, where he was awarded the Nobel prize in physiology or medicine for his work, and has subsequently been suitably named as the “Warburg Effect.”
The Warburg Effect describes cancer cells that are characterized by their decreased mitochondrial respiration, increased glycolysis (production of ATP without the use of molecular oxygen) and excessive lactate production.
Theralase’s TLC-2000 Cold Laser Therapy (“CLT”) was used to irradiate both in vitro GlioBlastoma Multiforme (“GBM”) Rat Glioma (‘RG2”) brain and also transitional cell carcinoma bladder cancer cells (T24). The data below is for GBM RG2 cancer cells, but the CLT treatment of human bladder cancer cells rendered similar results on the Warburg Effect (data not shown)
Post treatment analysis of both of these cancer cell lines demonstrated a 20% decrease in the glycolysis rate (measured by a decrease in lactate production) and a 20% increase in mitochondrial respiration, leading to a shift in their metabolism (from cancerous to normal), indicating a reversal of the aptly named, Warburg Effect.
During the transformation of cells from normal existence to cancerous, the Warburg Effect is associated with numerous metabolic gene expressions necessary for glycolysis, such as, the upregulation of:
1) Glucose Transporter 1 (“GLUT1”) (used to increase glucose uptake and the glycolysis rate)
2) MonoCarboxylate Transporter 1 (“MCT1”) (used to increase lactate (necessary for all main aspects of carcinogenesis) transport outside of the cell)
3) Pyruvate Kinase M2 (“PKM2”) (Glycolytic enzyme crucial for Warburg Effect glycolysis)
4) HexoKinase-2 (“HK2”) (Glycolytic enzyme crucial for Warburg Effect glycolysis)
Theralase’s CLT was shown to downregulate glycolysis-related genes by approximately 20%.
In addition, Theralase’s CLT was shown to downregulate known oncogenes (genes that promote cancer progression) such as:
1) c-Myc (“master regulator” which controls many aspects of both cellular growth and cellular metabolism)
2) HIF-1a (responsible for cellular and developmental response during hypoxia)
3) mTOR (a key metabolic and bioenergetic checkpoint which positively regulates protein, lipid and nucleotide synthesis)
Theralase’s CLT was also shown to increase the expression of known tumor suppressor genes (genes that inhibit cancer progression and are normally inhibited in cancer cells) such as p53, which regulate cell metabolism by lowering the rates of glycolysis and augmenting mitochondrial respiration. p53 downregulates cellular glucose uptake and the expression of other glycolytic enzymes.
Theralase’s CLT was shown to decrease oncogene expression by approximately 20% and increase tumor suppressor expression by 15%.
To evaluate the effect of Theralase’s CLT in an in vivo animal model, mice were injected with colorectal cancer cells (CT.26WT) and treated with Theralase’s CLT.
It was observed that Theralase CLT treated mice were able to survive on average twice as long versus untreated mice, due to a significant growth delay in tumour size caused by the anti-cancer effect of Theralase’s CLT (reversing the Warburg Effect).
Survival analysis after tumor injection:
Based on the reported data, Theralase researchers have established, in a preclinical model, that Theralase CLT is able to:
1) Reverse the Warburg Effect (Decrease glycolysis (measured by reduced lactate production and increased mitochondrial respiration)); thereby, shifting the metabolic state towards normal cell energy production and away from cancer cell energy production
2) Downregulate the genes associated with the Warburg Effect
3) Downregulate oncogenes
4) Increase the expression of tumor suppressor genes
5) Significantly delay tumour growth
Thus, significantly increasing the overall survival rate of animals, exposed to cancer, who have been treated with Theralase’s CLT.
Mark Roufaiel, Ph.D., Research Scientist, Theralase stated, “A majority of cancer cells produce energy through a high rate of glycolysis and lactic acid production, a phenomenon known as the Warburg Effect. Our preclinical results clearly demonstrate that Theralase’s CLT is able to reverse the Warburg Effect and hence delay tumour progression. This new data changes the previous belief that CLT has carcinogenic effects and that CLT should not be used to treat cancerous tumours. In this latest research, we present preclinical evidence that Theralase’s CLT, in the proper clinical doses, is safe and effective in the reversal of the Warburg Effect and can modulate the cellular metabolism of cancer cells to selectively inhibit the Warburg Effect, in laboratory cancer models. This shows a significant untapped potential for Theralase’s CLT to be used as a safe, effective and elegant way to fight cancer.”
Arkady Mandel, MD, Ph.D., D.Sc., Chief Scientific Officer, Theralase stated that, “In our preclinical research, we employed knowledge garnered from exercise physiology in the treatment of patients suffering from muscular fatigue and pain, conditions that increase lactate production. Increased glucose uptake and the accumulation of lactate, even under normoxic conditions (aerobic glycolysis or the Warburg Effect), is a common feature of cancer cells. After a hiatus of several decades, there is a renewed interest in reversing aerobic glycolysis (Warburg Effect) as a key strategy to destroying cancer.”
Dr. Mandel went on to say that, “There are five key cellular indicators of the Warburg Effect in carcinogenesis (the formation of cancer):
1) increased glucose uptake
2) increased glycolytic enzyme expression and activity
3) decreased mitochondrial respiration
4) increased lactate production, accumulation and release
5) upregulation of genes, such as monocarboxylate transporters MTC1 and MCT4, for lactate exchange.
Lactate is the key metabolic compound involved in the above processes leading up to carcinogenesis; specifically: angiogenesis (development of new blood vessels), immune escape, cell migration, metastasis (cancer spread to other tissues) and self-sufficient metabolism.
Accordingly, we strongly believe that technologies, like Theralase CLT, which have been proven preclinically to reverse the Warburg Effect, should be prioritized by researchers for the discovery of next generation anti-cancer therapeutic strategies. In our preclinical research, we used Theralase CLT as a modulator of cellular metabolism and were able to identify specific parameters that reverse the Warburg Effect, in laboratory cancer models.
The results of our preclinical research demonstrate a significant unrealized potential of CLT, a therapeutic modality with over 50 years of clinical history that has been well recognized by Health Canada and the FDA as a safe and effective treatment of patients with chronic pain, now being able to provide an elegant way to fight cancer.
Theralase, by building on the technology that commenced their early success in pain management, has now demonstrated the ability to employ this technology as a disruptive innovation in the destruction of cancer.”
Roger Dumoulin-White, P.Eng., President and CEO, Theralase stated, “The combination of technologies from our Therapeutic Laser Therapy (“TLT”) division and our Photo Dynamic Therapy (“PDT”) division is a pleasant surprise. Preclinical and clinical research have always been the drivers of innovation within our organization and the data strongly supports the use of Theralase CLT, according to very specific clinical dose specifications derived by Theralase, to be used pre-emptively to lessen the ability of cancer cells to defend themselves against PDT and the immune system, by reversing the Warburg Effect.”
Into da ground
Theralase Anti-Cancer Vaccine Validated in Colorectal Cancer
Toronto, Ontario (FSCwire) - Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotech company focused on the commercialization of medical lasers to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer has announced that it has validated its new anti-cancer vaccine in an additional animal cancer model for colorectal cancer.
The new anti-cancer vaccine was validated in a subcutaneous, colorectal cancer cell (CT.26 WT) mouse model, demonstrating that Theralase’s new anti-cancer vaccine is not solely limited to GlioBlastoma Multiforme (“GBM”) brain cancer cells (previously validated in a Rat Glioma (“RG2”) model), but is also able to be adapted to other types of cancer cell lines, in which the animal’s immune system is stimulated and subsequently programmed to hunt, recognize and destroy cancer cells of specific types.
In Theralase conducted research, it was demonstrated that the new anti-cancer vaccine was able to increase well established biomarkers of the immunological destruction of cancer cells, such as increased Adenosine TriPhosphate (“ATP”) release and increased calreticulin surface expression for colorectal cancer cells.
Extracellular ATP quantification:
To view the graphic in its original size, please click here
Cell surface expression of calreticulin was increased by 87% over control:
To view the graphic in its original size, please click here
To evaluate the new anti-cancer vaccine in animals, mice were vaccinated and then implanted with colorectal cancer cells utilising an established model of colorectal carcinoma. Vaccinated mice were able to survive 58% longer on average than non-vaccinated mice. This increase in survival was due to a significant growth delay in tumor size.
Survival analysis after tumor induction:
To view the graphic in its original size, please click here
Tumour volume after tumour induction:
To view the graphic in its original size, please click here
Excluding skin cancers, colorectal cancer is the third most common cancer diagnosed in both men and women in the United States. The American Cancer Society’s estimates that the number of colorectal cancer cases in the United States for 2017 are:
95,520 new cases of colon cancer
39,910 new cases of rectal cancer
Colorectal cancer is the third leading cause of cancer-related deaths in women in the United States and the second leading cause in men. It is expected to cause about 50,260 deaths in 2017.
Mark Roufaiel, Ph.D., Research Scientist, Theralase stated, “The latest data supports our understanding that the new anti-cancer vaccine approach developed by Theralase is able to induce a potent, anti-tumour, immune response that can significantly delay recurrence and progression of various metastatic tumors, leading to a significant increase in animal survival. This new research demonstrates that the Theralase anti-cancer vaccine approach is not limited to any specific type of cancer and is thus able to be adapted to be effective for the treatment of various cancers.”
Manjunatha Ankathatti Munegowda, Ph.D., DVM, Research Scientist, Theralase, stated that, “The Theralase anti-cancer vaccine has now demonstrated significant therapeutic benefit in both an aggressive RG2 GBM brain cancer animal model and in a colorectal tumor animal model. This finding supports the understanding that this vaccine has utility for multiple cancer indications, irrespective of the presence of genetic mutations, physical location of the cancer or the origin of the disease. As an anti-cancer vaccine that is intramuscularly injected into an animal, it is able to directly stimulate the immune system to hunt, recognize and destroy cancer cells of a specific type and in doing so, increase the animal’s quality of life and overall survival.”
Arkady Mandel, M.D., Ph.D., D.Sc., Chief Scientific Officer, Theralase stated: “The scientific and clinical objectives were clearly defined by our scientific research team, prior to undertaking a project of this magnitude; however, there was always one critical question that remained, ‘How do we systematically address the mutations that are unique to an individual patient’s tumour, but at the same time develop a anti-cancer vaccine that has the ability to directly influence several amplification pathways to stimulate a whole body anti-cancer immune response in patients with various forms of cancer?’ I’m pleased to report that we were able to answer this question, in animals, in the form of Theralase’s anti-cancer vaccine, which has now been validated in two distinct animal cancer models; specifically: GBM brain cancer and colorectal cancer and both have demonstrated a significant increase in overall survival for two distinct animal species (mice and rats). The next objective of our research will be to validate whether the significant results we have observed in our animal models is able to be successfully translated to humans. The hope is that Theralase’s anti-cancer vaccine will demonstrate significant clinical activity in humans, as well, with improvements in patient outcomes versus current standards of care. As we advance our scientific research, we are steadily overcoming the obstacles on our road to success, with the realization that fully personalized anti-cancer vaccines for numerous human cancers are within our grasp and are quickly becoming a reality.”
Roger Dumoulin-White, P.Eng., President and CEO of Theralase stated that, “The additional validation of the new anti-cancer vaccine, in colorectal cancer, only emboldens the entire Company that the path we have chosen is the correct one and as a result we all look forward to making a significant stride forward in the war on cancer. I look forward to advancing Dr. Mandel’s and his team’s cutting-edge scientific research to the clinic, in the form of a Phase Ib clinical study and successfully demonstrating these significant results clinically in humans.”
Bottom found, I'm im again
IBC Advanced Alloys Reports Fiscal Q1 2018 Financial Results
Highlights
IBC posted a 36% increase in year-on-year sales revenue, with Engineered Materials division sales up 142% and Copper Alloys division sales 7% higher.
The Company swung to a positive gross margin of 9% on a consolidated basis in the quarter, compared to a negative 15% gross margin in the comparable year-ago period, and a 0% gross margin for all of FY2016.
The Company narrowed its operating loss in the quarter to US$0.02 per share, as compared to a US$0.07 loss in the preceding quarter and a US$0.05 loss in the comparable year-ago period.
Significant personnel issues in one key manufacturing department of the Copper Alloys division early in the quarter slowed progress toward profitability, but the Company is working toward a goal of achieving profitability in the quarter ending March 31, 2018.
FRANKLIN, IN [DATE] – IBC Advanced Alloys Corp. (TSX-V: IB; OTCQB: IAALF) (“IBC” or the “Company”) a leading beryllium and copper advanced alloys company, announces its financial results for the quarter ended September 30, 2017, which is the Company’s first fiscal quarter of 2018.
Sales increased 36% in the quarter as compared to the quarter ended September 30, 2016, with Engineering Materials division sales expanding by 142%. Both operating divisions swung to positive gross margins from negative gross margins in the year-ago period. The Company narrowed its per-share loss in the quarter on both a sequential and year-on-year basis, and is working to achieve profitability in the quarter ending on March 31, 2018.
“We made good progress in this past quarter, in spite of some challenges, and we continue to advance toward our goals of becoming profitable and continued market penetration,” said Major General Duncan Heinz (USMC, Ret.), President, CEO and Director of IBC. “Engineered Materials division sales grew sharply in the quarter, and that division is now very close to profitability. Our Copper Alloys division also is trending in the right direction now that they are largely past a temporary loss of personnel on the factory floor in our Franklin, IN plant that unexpectedly impacted them last quarter.”
“Corporate costs have decreased significantly, and we achieved a significant swing to positive gross margins across both operating divisions,” the General noted. “I think it is reasonable to expect profitability in the fiscal third quarter, given that there are likely some product delivery timing issues that we could encounter in December that might delay recognition until Q3. That said, I very much like IBC’s trajectory, and I expect we will be able to show additional progress toward profitability in fiscal Q2.”
“The challenges we faced in the first month of fiscal Q1 were the result of a combination of significant real-life personnel issues in one key manufacturing area in the Copper Alloys division,” the General said. “As a result, we failed to deliver on orders in July, which pushed deliveries beyond due dates. As a result, orders for Q2 flattened somewhat because of our temporary inability to meet delivery commitments. However, I am very pleased to report that customers have remained loyal, and we are now seeing orders on the rise, including orders from both existing and new customers that are driven in part by our expanded production capabilities with the solution annealing furnace and quench tank that we installed earlier this year.”
“Our EMC division is really starting to hit its stride now, and we are continuing to improve rate, throughput, and performance with our upgraded beryllium-aluminum alloy furnace and with the advanced support infrastructure we have deployed along with it,” he said. “In addition to delivering our innovative precision-cast Beralcast® products to current customers, we continue to work toward commercialization of additional Beralcast® products for other defense and non-defense applications.”
“Our team’s work to develop scandium-contained alloys is also progressing,” General Heinz added. “While our business strategy in this effort must remain confidential at this point, we will make announcements as appropriate. What I can say with confidence is that the markets are there for the innovative alloys we intend to develop. We have a solid plan to penetrate our target markets with these products.”
The Company’s fiscal Q1 2018 financial statements and management’s discussion and analysis are available for review at www.sedar.com. Below are some highlights of the results.
Fiscal Q1 2018 Highlights
(All financial amounts in US$)
Consolidated Results
Sales revenue for the quarter totaled $4.3 million, a 32% increase over sales of $3.6 million for the quarter ended on September 30, 2016, and a 2.7% increase over the preceding quarter.
The Company narrowed its loss in the quarter to $602,000, or ($0.02) per basic and diluted share. This compares to a loss of $1.6 million, or ($0.05) per share, in the comparable year-ago period, and a loss of $2.2 million, or ($0.07) per share, in the preceding quarter.
Gross profits and gross margin swung to positive territory as compared to the quarter ended September 30, 2016. Gross profit totaled $396,000, compared to a gross loss of $479,000 in the year-ago period. Gross margin rose to 9%, compared to a gross margin of negative 15% in the comparable year-ago period, a gross margin of 6% in the preceding quarter, and a 0% gross margin for FY2016.
Corporate expenses decreased 55% to $198,000 from expenses of $440,000 in the quarter ended September 30, 2016, largely due to savings achieved by closing the Company’s Vancouver office in fiscal 2017. Corporate expenses were higher on a sequential basis, however, as the Company recovered professional fees expense at its fiscal year end.
As of September 30, 2017, the Company reported a working capital deficiency of $867,000, including cash of $463,000. This compares to a working capital deficiency of $1.5 million at June 30, 2017. The Company noted that it expects to seek additional funds in the short-term to finance working capital and growth initiatives, and is examining a range of options including debt financing, possible asset sales, and other alternatives.
Copper Alloys Segment Results
Copper Alloys sales increased 7% in the quarter to $2.9 million, compared to sales of $2.7 million in the quarter ended September 30, 2016. Sales declined 8% from $3.1 million in the preceding quarter, due largely to labor shortages in the Company’s Franklin forging facility early in the quarter. This was partially offset by increased sales through the Company’s Royersford, PA foundry, particularly to customers supplying the material. Management believes that customers delayed orders during this time, and order bookings are expected to improve.
Other financial results for the quarter, on a year-on-year basis, included these:
Average selling prices increased 10% in the quarter, partially offsetting a decline in overall sales volume. Sales to metal service center customers decreased slightly, while most other market sectors improved, particularly original equipment manufacturers.
Operating losses were cut by 46% to a loss of $269,000 from a loss of $498,000;
Cost of sales declined 3.6% to $2.6 million from $2.7 million;
Order bookings increased 15% to $3.1 million from $2.7 million. Order backlog in the quarter decreased 20% to $2.9 million from $3.6 million in the preceding quarter; and
Gross margin for Copper Alloys swung to a positive 8% from a negative 2%.
Looking forward, the Company expects its Copper Alloys division sales to increase as it begins shipping all awarded forged and machined copper alloy products to a Fortune 100 electronics manufacturer. IBC has been shipping two qualified parts to this customer and has produced samples of the remaining four parts that have been ordered, and are currently undergoing first article inspection.
Engineered Materials (EMC) Segment Results
EMC division sales rose sharply in the quarter, up 142% to $1.5 million, compared to $598,000 in the year-ago period. Sales also increased sequentially, up 34% from $1.1 million in the quarter ended June 30, 2017. Sales volumes of both commercial castings and aerospace and defense castings increased significantly. Gross profit increased $593,000, from a loss of $418,000 in the year-ago period to a profit of $175,000, due to the volume increases. Operating losses decreased $591,000, from a loss of $659,000 in the year-ago period to a loss of $68,000, due to improved gross profit.
While the company completed structural upgrades and sub-systems to its new beryllium-aluminum alloy furnace in May 2017, it temporarily halted production as the existing furnace components were removed and the new components installed. While production was halted, it continued to ship commercial castings from stock. Sales volumes of commercial castings increased slightly, while sales volumes of aerospace and defense castings increased 267%. Gross profit improved $319,000 as production resumed. Operating losses decreased by 84% to a loss of $68,000, from a loss in the preceding quarter of $430,000. Gross margin improved sequentially to a positive 12% from a negative 13%.
Following installation and commissioning in May 2017 of a new vacuum induction melting (VIM) furnace in the division’s Wilmington, MA production facility, the Company also installed advanced automation and real-time process monitoring systems, thereby facilitating a significant step-change in capability. With improved cycle time, the daily melt capacity in the EMC division has increased by 25%. Combined with additional shifts, reduced maintenance down-time, and expected yield improvements, this capital improvement has positioned EMC to significantly increase output to meet increased customer demand.
The Company reported that it is continuing to make deliveries to Lockheed Martin of azimuth gimbal housings for the F-35 Lightning II jet fighter under the Low Rate of Production (LRIP) lot 11. This the third contract awarded to the Company by Lockheed Martin for the precision-cast beryllium-aluminum alloy (Beralcast®) part that is integrated into the F-35. The first contract, awarded in September 2014, was for LRIP lots 7 and 8, and the second contract awarded in August 2015 was for LRIP lots 9 and 10.
In addition to the Company’s previously announced contracts with Lockheed Martin and Raytheon, it currently is pursuing other sales opportunities with several defense and aerospace companies.
For more information on IBC and its innovative alloy products, go here.
On Behalf of the Board of Directors:
"Duncan Heinz”
Duncan Heinz, President, CEO and Director
Do we close in red today? Loool unbelievable
Danke rubbelwürmchen
2 CAD im Blick Anfang (Januar/Februar) 2018
Might be, but isn't raising money (at this level) for "just" an IR compaign suicide?
They should have done it earlier.
shoulda coulda woulda
By the way, thanks for your reply and enjoy your stay in spain!
Walter, wasn't niocorp planning to start a big campaign right after the CC, even in asia?
Its too quiet from Jim Sims side, we need continues news flow, independent of the magnitude of the news.
It feels like there wont be any news coming till the beginning of 2018.
From my side, Jim isn't doing a good job at least by informing us and being transparent.
I mean he was reading this board some months / year ago, why is he not getting some inspiration?
A lot of people had great ideas of how to act and what kind of information would be helpful.
But IR was still quiet and every person has to contact themself instead of broadcasting it like a IR campaign.
Its nothing personal against Jim, its just my feeling of IR at the moment
Maybe its only Elon Musk wearing a MarkSmith mask :D, promising the next big thing without delivering it.
I'm ready to buy back at 0,25 CAD to 0,3 CAD
Hallo walterc,
nobody hates you or any other person here on the board.
The problem that I do have is, that if Mark would be doing it correctly, we would not be able to dump the share price.
We spent almost 1-2 years and multiple millions to optimize the FS which leads to higher costs and lower IRR.
Now we are late in the game, at the start of tax loss selling and land of nowhere regarding financing + pressure of current sp.
Could you please give us 3 differnt reasons why we should stay / buy in Niocorp, except the common mentioned reasons like, "the resource is worth billion" or "world class management" or "we have 75% offtake of our niobium ", ...
I guess these facts are known to everybody, but worth nothing at the moment because they dont calm any investor any longer.
I may be an idiot, but I mentioned it to often, that we spent too much time optimizing or spending millions on that. We should go with a less optimal offer than going bankruptcy.
That is just an opinion of an idiot.
Maybe because they dont know if they will receive the supplement, but an other company.
Or maybe they want it go down even more to get it even cheaper and to put more pressure on mark.
This is the last night where all political camps have to agree on all political topics.
Angie is on hibernate at the moment. Havent seen any statement from her since some weeks but all other blaming each other.
Difficult but we will know tomorrow
I agree on what Landmark said.
How should he sell his million of shares when even 500 smash the price down ?
Maybe we are bought out for 1 CAD at least.
I guess a big company buys us for "free" while Mark optimizes our paper value :D
I guess Mark waits till the lowest possible shareprice to announce a new pp :D
Maybe he thinks the lower the shareprice the better it is :D
We are on it Putz :D
Amen Advo
Thanks a lot photo
Ok, name one thing I lied about, you cant
Hahaha you made my day berNICE
Oh i do have problem with bullsh** stocks :D
No, this is a "Mark Smith" company, so i'm used to it (delays)
Ok you okey with a financing at these sp level of lets say 0,35 USD?
Even if they raise the money in steps, and they will go for a 200m debt package, then there will be 100 m in equity which means 285m new shares.
Are you ok with that?
If they raise it all at once, there will be up to 1,12 billion new shares + the current ones.
Are you ok with worthless shares?
Your order should be filled now :D
Still no official news about scandium tests.
Hi Revello,
Thanks for the information.
Do you know the current cash base and burn rate per month?
Nice, thank you
Easy come easy go
Trading resumed
Wait for more attention and restart trading with even more buying pressure
Donno, but I guess to much volatility.
Stock is on halt at the moment